Flexibility to Choose an Appropriate Dosing Regimen
The recommended dose for EYLEA in DR is 2 mg administered by intravitreal injection Q4 for the first 5 injections, followed by 2 mg Q8.1
Although EYLEA may be dosed as frequently as 2 mg Q4 (≈every 25 days, monthly), additional
efficacy was not demonstrated in most patients when EYLEA was dosed Q4 compared with Q8.
Some patients may need Q4
(monthly) dosing after the first 20
weeks (5 months).
Q4, every 4 weeks; Q8, every 8 weeks;
Only EYLEA Is Approved to Treat 4 VEGF-Driven Retinal Diseases With 1 Single-Dose–Strength PFS
The pre-filled syringe (PFS) offers a more convenient way to prepare EYLEA for administration when compared with vials1
- Fewer components to handle
- Helps eliminate multiple preparation steps
One dosage strength may
help1
- Simplify ordering and billing
- Streamline inventory management
Preparation of the single-dose, pre-filled syringe for intravitreal administration
VEGF, vascular endothelial growth factor.
A demonstrated safety profile1
A library of resources for
you and your patients
Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.
